{"DataElement":{"publicId":"13203414","version":"1","preferredName":"Pharmacologic Management Strategy Use Type","preferredDefinition":"A description of the type of pharmacologic management strategies that were used.","longName":"PHRM_MGMNT_STRGY_USE_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"13203411","version":"1","preferredName":"Pharmacologic Management Strategy Use","preferredDefinition":"A health/illness/pain management principle specifically directed at the management of pharmacologic agents in maximizing beneficial outcomes and minimizing unfavorable effects._A plan of action intended to accomplish a specific goal.:A manner, or usual, or accepted practice of using something.","longName":"13203410v1.00:2234899v1.00","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"13203410","version":"1","preferredName":"Pharmacologic Management Strategy","preferredDefinition":"A health/illness/pain management principle specifically directed at the management of pharmacologic agents in maximizing beneficial outcomes and minimizing unfavorable effects._A plan of action intended to accomplish a specific goal.","longName":"C21090:C147914","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacologic Management","conceptCode":"C21090","definition":"A health/illness/pain management principle specifically directed at the management of pharmacologic agents in maximizing beneficial outcomes and minimizing unfavorable effects.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Strategy","conceptCode":"C147914","definition":"A plan of action intended to accomplish a specific goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6F70693-E245-1FA8-E053-731AD00A7798","latestVersionIndicator":"Yes","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234899","version":"1","preferredName":"Use","preferredDefinition":"Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.","longName":"C25340","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Use","conceptCode":"C25340","definition":"A manner, or usual, or accepted practice of using something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-7486-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-15","modifiedBy":"ONEDATA","dateModified":"2005-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6F70693-E246-1FA8-E053-731AD00A7798","latestVersionIndicator":"Yes","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":"2023.5.31 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13203413","version":"1","preferredName":"Pharmacologic Management Type","preferredDefinition":"A health/illness/pain management principle specifically directed at the management of pharmacologic agents in maximizing beneficial outcomes and minimizing unfavorable effects._Something distinguishable as an identifiable class based on common qualities.","longName":"13203413v1.00","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dexamethasone","valueDescription":null,"ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6F71A51-D384-21FE-E053-731AD00A1E37","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-03-15","deletedIndicator":"No"},{"value":"Hydroxyurea","valueDescription":null,"ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6F71A51-D385-21FE-E053-731AD00A1E37","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-03-15","deletedIndicator":"No"},{"value":"None of the above","valueDescription":null,"ValueMeaning":{"publicId":"5913672","version":"1","preferredName":"None of the Above","longName":"5913672","preferredDefinition":"None of the choices above are suitable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None of the Above","conceptCode":"C133298","definition":"None of the choices above are suitable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5499ACEF-10D1-1155-E053-F662850A3955","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6F71A51-D386-21FE-E053-731AD00A1E37","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-03-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13203412","version":"1","preferredName":"Pharmacologic Management Type","preferredDefinition":"A health/illness/pain management principle specifically directed at the management of pharmacologic agents in maximizing beneficial outcomes and minimizing unfavorable effects._Something distinguishable as an identifiable class based on common qualities.","longName":"13203412v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacologic Management","conceptCode":"C21090","definition":"A health/illness/pain management principle specifically directed at the management of pharmacologic agents in maximizing beneficial outcomes and minimizing unfavorable effects.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6F70E0E-4D86-2094-E053-731AD00A5102","latestVersionIndicator":"Yes","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6F70E0E-4D87-2094-E053-731AD00A5102","latestVersionIndicator":"Yes","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":"2023.5.31 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What type of pharmacologic management strategies were used?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Which of the following management strategies did the patient receive?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6F72B7B-D70D-23D7-E053-731AD00A8169","latestVersionIndicator":"Yes","beginDate":"2023-03-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":"2023.5.31 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}